Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Terminated Phase 2 Interventional Results available

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

NCT00603408
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Radiation Therapy, Mastectomy
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 22, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

NCT02996825
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacological Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Duarte, California • Upland, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Vitamin D vs Standard Dose Vitamin D Study

NCT01988090
View directory record Official record
Conditions
Breast Cancer
Interventions
800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

NCT00394082
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABI-007, Bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Melbourne, Florida • Ocoee, Florida • Niles, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Tamoxifen, Prophylactic Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography

NCT01669148
View directory record Official record
Conditions
Breast Cancer
Interventions
Tomosynthesis, Conventional
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer

NCT06228768
View directory record Official record
Conditions
Postmenopausal, Breast Cancer
Interventions
Acupressure
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 22, 2026, 6:32 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

NCT04740918
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab Emtansine, Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 22, 2026, 6:32 PM EDT
Completed No phase listed Observational

Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer

NCT02050620
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 22, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
162
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors

NCT01177124
View directory record Official record
Conditions
Breast Cancer
Interventions
MBSR 6 Weeks Program
Behavioral
Lead sponsor
Cecile Lengacher
Other
Eligibility
21 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 22, 2026, 6:32 PM EDT
Completed No phase listed Observational

Sensory Morbidity Following Breast Surgery

NCT00625924
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 22, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat - LBH589
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 22, 2026, 6:32 PM EDT
Active, not recruiting No phase listed Observational

Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)

NCT03927768
View directory record Official record
Conditions
Breast Cancer
Interventions
Predictive Model, Breast Imagers
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 6:32 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2

NCT06082882
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
Education, Navigation to clinic
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

NCT01000662
View directory record Official record
Conditions
Breast Cancer
Interventions
Daily Radiation Therapy, Weekly Radiation Therapy
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 22, 2026, 6:32 PM EDT
Terminated Not applicable Interventional Results available

Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention

NCT04092816
View directory record Official record
Conditions
Metastatic Breast Cancer, Parenting
Interventions
FAMILY Intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00004085
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 22, 2026, 6:32 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 22, 2026, 6:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Combined Breast Cancer Risk Study

NCT03067389
View directory record Official record
Conditions
Hereditary Cancer
Interventions
Diagnostic test
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 84 Years · Female only
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Fayetteville, Arkansas • Boynton Beach, Florida • Hyannis, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Drug 1: LY3023414; Drug 2: Prexasertib
Combination Product
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 22, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

NCT00483223
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 22, 2026, 6:32 PM EDT